Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Completed 5Withdrawn 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 3Gynecologic 2

Conditions

Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Adenocarcinoma 3Ovarian Neoplasms 2Endometrial Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Completed × EC145 × Clear all
NCT01002924 2021-04-08

Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)

Endocyte

Phase 2 Completed
1 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01577654 2021-04-01

TARGET

Endocyte

Phase 2 Completed
203 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT00511485 2015-02-27

Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)

Endocyte

Phase 2 Completed
43 enrolled
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00507741 2015-01-07

Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)

Endocyte

Phase 2 Completed
49 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT00722592 2015-01-07

PRECEDENT

Endocyte

Phase 2 Completed
162 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡